AsclepiX Therapeutics is a Baltimore-based biotechnology company dedicated to revolutionizing the treatment of ocular diseases through the development of innovative therapies. Using cutting-edge computational biology methods, they have identified potent peptides that regulate vascular homeostasis, aiming to empower patients worldwide to live their best lives.
With their lead candidate, AXT107, AsclepiX Therapeutics targets retinal vascular diseases by inhibiting pro-angiogenic factors and activating vessel stabilizing receptors. Their approach offers the potential for improved vision gains, reduced vascular permeability, and suppression of inflammation, with the goal of minimizing treatment burden for patients. Led by a team of experienced biomedical and pharmaceutical executives, AsclepiX Therapeutics is committed to advancing the clinical development of these novel therapeutics to address significant unmet needs in global healthcare.
Generated from the website